post-template-default,single,single-post,postid-3152,single-format-standard,strata-core-1.1.1,strata-child-theme-ver-1.0.0,strata-theme-ver-3.4,ajax_fade,page_not_loaded,wpb-js-composer js-comp-ver-6.7.0,vc_responsive

Global growth for Seqirus drives further expansion in central Maidenhead

10:38 07 December in Berkshire, News
Left to right: Mrs Laura Lion (Mayoress, The Royal Borough of Windsor and Maidenhead), Councillor Paul Lion (Mayor, The Royal Borough of Windsor and Maidenhead), Gordon Naylor (President, Seqirus), Gareth Ralphs (Partnership Manager, South East, DIT), Ken Lim (Senior Vice President, Seqirus)

New premises acquired for recruitment drive of up to 200 new UK employees over 2019-20

Seqirus, a global innovator in influenza vaccines, is expanding its global headquarters in Maidenhead to support its rapid growth. It has outgrown its original offices – opened three years ago by constituency MP and Prime Minister Theresa May – due to its continuing global expansion. Over the past two years, the number of employees at Seqirus headquarters has doubled to over 220 staff.

The extensive new, high technology offices in Maidenhead town centre – adjacent to the current Seqirus HQ – total 25,000 square feet and have the capacity for up to an additional 250 employees. Cutting the ribbon, Seqirus President Gordon Naylor, said: “I am very pleased to open this new office, which will strengthen our ability to support our swiftly growing influenza vaccines business across the globe. I think our employees will be grateful too, as it was getting a little cramped in our original building!”

Expansion in Maidenhead follows announcements this year of major new investments in the company’s Liverpool manufacturing plant – one of the largest in Europe – and at its Holly Springs production site in North Carolina, U.S. In total, Seqirus plans to add up to 200 new jobs in the UK to its current workforce of 900 over the next two years.

David Sheppard, Deputy Head of Life Sciences at the Department for International Trade, said: “We were pleased to work with Seqirus to establish their presence in Maidenhead and welcome the news of the company’s ongoing expansion. The life sciences sector is important to the UK and we are committed to supporting its continued growth, particularly in terms of exports and inward investment.”

Mr Naylor commented: “We are not only adding jobs here in Maidenhead, but also in Liverpool and at other Seqirus sites around the globe. We are achieving this by making world-class influenza vaccines, which help prevent serious illness, save lives and relieve winter pressures on health systems around the world.”

Paul Britton, CEO, Thames Valley Chamber of Commerce, said: “Having supported the DIT team who in turn helped secure the original investment by Seqirus, we are especially pleased the business is investing further and creating more highly skilled jobs here in the Thames Valley. Their expansion strengthens our place as one of the UK’s and Europe’s most innovative economy’s, raising the intensity of research and development in the region. This news adds to the weight of action the Thames Valley is involved in and is also reported in the most recent Life Sciences Sector Deal 2; which includes the Chamber’s own work in leading partners in developing a Thames Valley life sciences sector deal back into Government. We are proud of the strength and depth of our globally significant life sciences and healthcare cluster for which Seqirus is a valued partner.”